Green Cross Corporation – Company Intelligence Brief

1. Business Overview

Green Cross Corporation is a Korean biopharmaceutical company operating in the healthcare sector. Based on the financial statement structure showing consolidated accounts across multiple subsidiaries, the company appears to operate as a diversified healthcare group. The company's ~1.73 trillion KRW market capitalization positions it as a mid-cap player in Korea's pharmaceutical industry. [TRANSLATION NOTE: Specific business segment details and product lines are not included in the provided financial data and would require translation of additional Korean disclosure documents for complete accuracy.]

2. Financial Trend

Green Cross is experiencing a concerning financial trajectory. Revenue reached 1,680 billion KRW in FY2024, representing a modest 3.3% increase from 1,627 billion KRW in FY2023, but remains below the FY2022 level of 1,711 billion KRW.

More troubling is the profitability picture. Operating profit deteriorated to 32.1 billion KRW in 2024 (1.9% operating margin) from 34.4 billion KRW in 2023 (2.1% margin), a steep decline from 81.3 billion KRW in 2022 (4.7% margin). The company posted a net loss of 42.6 billion KRW in 2024, worsening from a 19.8 billion KRW loss in 2023, following a 69.4 billion KRW profit in 2022. This represents two consecutive years of losses after profitability in 2022.

The debt position has deteriorated significantly. Total liabilities increased to 1,263 billion KRW in 2024 from 1,103 billion KRW in 2023, while total equity declined to 1,481 billion KRW from 1,540 billion KRW. Non-current liabilities more than doubled to 493 billion KRW from 235 billion KRW year-over-year. The debt-to-equity ratio rose to approximately 85% from 72%, indicating increased financial leverage. Retained earnings fell sharply to 815 billion KRW from 873 billion KRW.

3. Ownership Structure

[TRANSLATION NOTE: Ownership structure and foreign ownership percentage data are not included in the provided DART filing excerpts. This information would require translation of the company's annual report shareholder section or separate disclosure documents typically filed in Korean.]

4. Key Risks

Profitability Crisis: The company has swung from 69 billion KRW profit in 2022 to consecutive annual losses totaling over 62 billion KRW in 2023-2024, with operating margins collapsing from 4.7% to under 2%. Without a clear turnaround, the company faces potential covenant breaches and equity erosion.

Deteriorating Financial Flexibility: The doubling of non-current liabilities to 493 billion KRW coupled with consecutive losses has materially weakened the balance sheet, limiting the company's ability to invest in R&D or weather further operational challenges without potentially dilutive capital raises.

5. Investment Consideration

Green Cross presents a distressed turnaround situation where investors must weigh the company's established market position against consecutive years of losses, margin compression, and rising leverage with no clear inflection point evident in the FY2024 results.